EntryPoint Capital LLC Purchases New Shares in Tyra Biosciences, Inc. (NASDAQ:TYRA)

EntryPoint Capital LLC acquired a new position in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 18,209 shares of the company’s stock, valued at approximately $253,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. KLP Kapitalforvaltning AS purchased a new stake in shares of Tyra Biosciences in the fourth quarter valued at $31,000. Raymond James Financial Inc. purchased a new stake in Tyra Biosciences in the 4th quarter worth about $761,000. Victory Capital Management Inc. boosted its position in Tyra Biosciences by 88.3% during the 4th quarter. Victory Capital Management Inc. now owns 56,640 shares of the company’s stock worth $787,000 after acquiring an additional 26,560 shares during the period. Alta Partners Management Company L.P. purchased a new position in Tyra Biosciences during the 4th quarter valued at about $56,716,000. Finally, US Bancorp DE acquired a new position in shares of Tyra Biosciences in the 4th quarter valued at about $50,000. 84.14% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. UBS Group started coverage on shares of Tyra Biosciences in a research report on Tuesday, January 7th. They set a “buy” rating and a $28.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target on shares of Tyra Biosciences in a research note on Tuesday, February 18th. Finally, Wedbush reissued an “outperform” rating and set a $30.00 price objective on shares of Tyra Biosciences in a research report on Friday. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $30.83.

Tyra Biosciences Trading Up 1.1 %

Shares of NASDAQ:TYRA opened at $9.77 on Friday. Tyra Biosciences, Inc. has a 1 year low of $9.49 and a 1 year high of $29.60. The firm has a fifty day moving average price of $12.46 and a 200 day moving average price of $16.36. The stock has a market capitalization of $494.39 million, a PE ratio of -6.07 and a beta of 1.09.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings data on Thursday, March 27th. The company reported ($0.43) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.05. On average, sell-side analysts forecast that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Nina S. Kjellson sold 5,401 shares of the firm’s stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $13.76, for a total value of $74,317.76. Following the sale, the director now directly owns 443,885 shares of the company’s stock, valued at approximately $6,107,857.60. This trade represents a 1.20 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 21,998 shares of company stock valued at $344,818 over the last 90 days. 15.40% of the stock is currently owned by company insiders.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.